EUVIMEDEUVIMED entdecken
Kohortenstudie

Survival Improvement of Stage IV Non-small Cell Lung Cancer in the Immunotherapy Era: A Retrospective Cohort Study in a US Population

Lianfang Ni iD, Zhigang Zhang, Dan Sun, Zhonghui Liu, Xinmin Liu

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-03027-0 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Advances in Therapy, 2024. Verfasst von Lianfang Ni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Peking University First Hospital, Beijing, 100034, China. nilianfang1@163.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Staging, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Immune checkpoint inhibitors (ICIs) greatly improved outcomes of stage IV non-small cell lung cancer (NSCLC) in randomized clinical trials. Limited data exists regarding the survival improvement of ICI use at the population level. METHODS: Clinical data of patients with pathologically confirmed stage IV NSCLC diagnosed in 2013 and 2017 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Survival outcomes were compared before and after ICI use to assess the survival improvement in the immunotherapy era in the real world. RESULTS: A total of 19,433 patients with stage IV NSCLC were included. Being female, age < 60 years, of American Indian and Asian or Pacific Islander race, married, non-squamous histology, without bone, brain, or liver metastases, and receiving chemotherapy were significantly associated with better prognosis in multivariable analyses. Propensity score matching (PSM) based on associated factors resulted in 8743 patients each in the non-immunotherapy and immunotherapy groups (1:1 ratio). After PSM, both overall survival (OS) (p < 0.001) and cancer-specific survival (CSS) (p < 0.001) were significantly improved in the immunotherapy group. The median OS (mOS) was 6.0 months in the non-immunotherapy group and 8.0 months in the immunotherapy group. The 1-, 2-, and 3-year OS rate was 29.0%, 14.2%, and 8.5% in the non-immunotherapy group, and 37.8%, 23.5%, and 16.7% in the immunotherapy group, respectively. Patients who were male, under 60 years old, married, white, had adenocarcinoma, had no bone or liver metastases, and received chemotherapy or radiation therapy were more likely to benefit from immunotherapy. CONCLUSIONS: Survival outcomes of patients with stage IV NSCLC were significantly improved in the immunotherapy era. Population-level benefits of survival varied among subgroups, and not all the increase in OS meant a clinically meaningful benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm StagingImmunotherapySEER ProgramHumansMaleFemaleMiddle AgedRetrospective StudiesAgedUnited StatesImmune Checkpoint InhibitorsAdultSurvival RatePrognosis

Stichwörter der Autor:innen

Immune checkpoint inhibitorsNon-small cell lung cancerSEERSurvival

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Geriatrics, Peking University First Hospital, Beijing, 100034, China. nilianfang1@163.com.
  • Department of Geriatrics, Peking University First Hospital, Beijing, 100034, China.

ORCID-Profile: Lianfang Ni

Zitieren

APA

Ni, L., Zhang, Z., Sun, D., Liu, Z., & Liu, X. (2024). Survival Improvement of Stage IV Non-small Cell Lung Cancer in the Immunotherapy Era: A Retrospective Cohort Study in a US Population. Advances in Therapy. https://doi.org/10.1007/s12325-024-03027-0

Vancouver

Ni L, Zhang Z, Sun D, Liu Z, Liu X. Survival Improvement of Stage IV Non-small Cell Lung Cancer in the Immunotherapy Era: A Retrospective Cohort Study in a US Population. Advances in Therapy. 2024. doi:10.1007/s12325-024-03027-0

BibTeX
@article{Ni2024,
  author = {Ni, Lianfang and Zhang, Zhigang and Sun, Dan and Liu, Zhonghui and Liu, Xinmin},
  title = {Survival Improvement of Stage IV Non-small Cell Lung Cancer in the Immunotherapy Era: A Retrospective Cohort Study in a US Population},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-03027-0}
}
Kostenlos starten →